



## Press release |

### **IBA SELECTED TO INSTALL THE FIRST GANTRY-EQUIPPED PROTON THERAPY SYSTEM OF RUSSIA, IN DIMITROVGRAD**

Winning this public tender underlines the recognition of IBA as the expert in developing the best Proton Therapy technologies at the best price

*For immediate release*

Louvain-la-Neuve, Belgium, October 13th – IBA (Ion Beam Applications S.A.) announces today that FSUE (Federal State Unitary Enterprise) “Federal Center of Nuclear Medicine Projects Design and Development” of the Federal Medico-Biological Agency (FMBA of Russia), has decided in favor of IBA to install a Proton Therapy center for the Ulianovsk Region. It will be the first gantry-equipped Proton Therapy center installed in Russia.

Following a rigorous public selection process, FMBA of Russia adjudicated to FSUE “Federal Center of Nuclear Medicine Projects Design and Development” of the FMBA of Russia the construction and the installation of the Federal High-Tech Medical Center in Dimitrovgrad. The Proton Therapy equipment will be delivered and installed by IBA and clinical operations will be performed by and under the responsibility of FMBA of Russia.

The center will be equipped with two gantry rooms, one dual beam treatment room and one small fixed beam room dedicated to eye treatments. It will also be equipped with the latest options for the IBA Nozzle technology, including the latest Pencil Beam Scanning system as well as a fully integrated solution, the PatLog™ concept that allows Particle Therapy system users to accomplish the largest part of the treatment preparation process outside the treatment room. This results in an improved throughput with an increased patient comfort. The Proton Therapy center will provide the population of Prevoljje and Ural region with leading-edge medical equipment in the area of cancer therapy and diagnosis. FSUE “Federal Center of Nuclear Medicine Projects Design and Development” of the FMBA of Russia won the tender for a total value of 6 917 200 000 Rubbles (164M Euros).

“The highly competent professional support and responsiveness given by IBA throughout our demanding tender procedure represents a strong guarantee for a successful and long lasting collaboration with them. We are now eager to see the Proton Therapy center opening its doors in 2014 and to provide this technology for the benefit of thousands of cancer patients in Russia”, said Mr Yuri Khalitov, head of the FSUE “Federal Center of Nuclear Medicine Projects Design and Development” of the FMBA of Russia.



## Press release |

“Winning this public tender underlines the recognition of IBA as an expert in building multiple Proton Therapy facilities anywhere in the world and we are eager to start building this first gantry-equipped Proton Therapy system of Russia. This technology offers undeniable improvements for patients and we are thrilled with this opportunity to contribute to improve the way we fight cancer in the world. IBA is delighted to have FMBA of Russia among its customers, said Pierre Mottet, Chief Executive Officer of IBA.

Proton Therapy is increasingly considered as the ultimate radiotherapy for cancer due to its superior dose distribution. Protons deposit the majority of their effective energy within a precisely controlled range, directly within the tumor, and better spare healthy surrounding tissue. Higher doses can be delivered to the tumor without increasing the risks of side effects and long term complications, improving outcomes and quality of life for patients. Unfortunately, very few patients can yet benefit from this type of treatment around the world.

IBA is committed to making Proton Therapy, the most accurate cancer treatment, available worldwide. Globally, IBA has sold 19 proton therapy centers, which represents over half of the clinical-based Proton Therapy facilities in the world.

### **ABOUT IBA**

IBA develops and markets leading-edge technologies, pharmaceuticals and tailor-made solutions for healthcare with a focus on cancer diagnosis and therapy. Leveraging on its scientific expertise, IBA is also active in the field of industrial sterilization and ionization.

*Listed on the pan-European stock exchange EURONEXT, IBA is included in the BelMid Index.*

*(IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).*

Website: [www.iba-worldwide.com](http://www.iba-worldwide.com)

### Contact

#### **IBA**

Thomas Ralet

VP Corporate Communication

Tel.: +32 10 47 58 90

Email: [InvestorRelations@iba-group.com](mailto:InvestorRelations@iba-group.com)